Due diligence report for investment: UK Biotech

The Challenge

Aptus Clinical was approached by a venture capital company to perform due diligence on a UK Biotech prior to making an investment decision

The Solution

An expert panel was rapidly convened to evaluate the data and produce a comprehensive report. This consisted of a pharmaceutical physician, translational scientist, clinical development and medical affairs experts, commercial director and the CEO of Aptus Clinical

The Outcome

The team produced an integrated evaluation of the company, its strategy within the oncology market, immuno-oncology technologies and current and future assets, including:

  • Assessment of competitive position
  • Technical capabilities and provenance of the team and company, including pre-clinical and early clinical competency
  • Short-, medium- and long-term potential of the company

The Feedback

The report was very well received by the client and the Biotech. As a result, we were invited to present our report to the Biotech’s Board and our ongoing relationship has included strategic drug development consultancy services

Client Feedback

Aptus Clinical pulled together an excellent team of drug development experts at very short notice, the quality of the report and the insights they provided were invaluable in supporting the discussions at our investment committee. We would certainly consider using Aptus Clinical again for similar due diligence projects

Partner , Venture Capital Company